In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J’s New Innovation Centers Test Immersion Theory Of Access

Executive Summary

Johnson & Johnson executives including Pharma Chairman and CSO Paul Stoffels explain how building a presence in innovation’s backyard will allow the health care giant to more easily and quickly access new assets and technologies. Can proximity to innovation make J&J more innovative?


Related Content

Deals of the Week Plays Favorites: Our Deals Of The Year Winners!
J&J Tries Transitioning To Health Care Solutions Firm Through JHI Subsidiary
J&J’s Boston “Deal-Making Machine” Backs Two Start-Ups
J&J Cultivates Early Stage Science Through A Trio Of Initiatives
BIO 2013: Biosimilars, Drug Pricing, Business Development And Innovation
Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
Biopharmaceutical Trends In 2012: Regulatory And Market Strides Paper Over Existential Dilemmas
Gloomy Neuroscience Partnering Outlook May Soon Brighten
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts